Use of ibandronate in the prevention of skeletal events in metastatic breast cancer

References

• AliSMEstevaFJHortobagyiGSafety and efficacy of bisphosphonates beyond 24 months in cancer patientsJ Clin Oncol2001193434711454892
   PubMed Web of Science ®Google Scholar
• AtulaSPowlesTPatersonAExtended safety profile of oral clodronate after long-term use in primary breast cancer patientsDrug Saf2003266617112814333
   PubMed Web of Science ®Google Scholar
• BamiasAKastritisEBamiaCOsteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factorsJ Clin Oncol2005238580716314620
   PubMed Web of Science ®Google Scholar
• BanerjeeDAsifAStrikerLShort-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicityAm J Kidney Dis200341E1812778436
   PubMed Web of Science ®Google Scholar
• BergstromBLichinitserMBodyJJIntravenous and oral ibandronate have better safety and tolerability profiles than zoledronic acid: evidence from comparative phase II/III trialsBone200638Suppl 1S68
   Web of Science ®Google Scholar
• BodyJJDielIJBellROral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancerPain20041113061215363874
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJLichinitserMRIntravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesAnn Oncol2003a14139940512954579
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJLichinitzerMOral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studiesBr J Cancer2004901133715026791
   PubMed Web of Science ®Google Scholar
• BodyJJKanisJDielIRisk reductions in metastatic breast cancer: mulitvariate Poisson regression analyes of oral and i.v. ibandroanteAm Soc Clin Oncol2003b2246
   Google Scholar
• BodyJJLichinisterMTjulandinSOral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: comparative bone turnover marker and safety dataBone200638Suppl 1S69
   Google Scholar
• BodyJJLichinitserMTjulandinSOral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastasesAnn Oncol20071811657117442659
   PubMed Web of Science ®Google Scholar
• BodyJJLouviauxIDumonJCDecreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemiaSupport Care Cancer2000839840410975689
   PubMed Web of Science ®Google Scholar
• ChangJTGreenLBeitzJRenal failure with the use of zoledronic acidN Engl J Med200334916769 discussion 1676–914573746
   PubMed Web of Science ®Google Scholar
• ClemonsMDranitsarisGOoiWA phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapyBreast Cancer Res Treat2008108798517473981
   PubMed Web of Science ®Google Scholar
• ColemanREMetastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treat Rev2001271657611417967
   PubMed Web of Science ®Google Scholar
• DaubineFLe GallCGasserJAntitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasisJ Natl Cancer Inst2007993223017312309
   PubMed Web of Science ®Google Scholar
• De CockEHuttonJCanneyPCost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapySupport Care Cancer2005139758615871033
   PubMed Web of Science ®Google Scholar
• DielIJBodyJJLichinitserMRImproved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancerEur J Cancer20044017041215251160
   PubMed Web of Science ®Google Scholar
• DielIJSolomayerEFBastertGTreatment of metastatic bone disease in breast cancer: bisphosphonatesClin Breast Cancer20001435111899389
   PubMedGoogle Scholar
• DurieBGKatzMCrowleyJOsteonecrosis of the jaw and bisphosphonatesN Engl J Med20053539910216000365
   PubMed Web of Science ®Google Scholar
• GranoMMoriGMinielliVBreast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclastsBiochem Biophys Res Commun2000270109710010772956
   PubMed Web of Science ®Google Scholar
• HillnerBEIngleJNChlebowskiRTAmerican Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancerJ Clin Oncol20032140425712963702
   PubMed Web of Science ®Google Scholar
• HiragaTWilliamsPJMundyGRThe bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastasesCancer Res20016144182411389070
   PubMed Web of Science ®Google Scholar
• HortobagyiGNTheriaultRLLiptonALong-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study GroupJ Clin Oncol1998162038449626201
   PubMed Web of Science ®Google Scholar
• HultbornRGundersenSRydenSEfficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter studyAnticancer Res19991933839210629624
   PubMed Web of Science ®Google Scholar
• LiptonABone metastases in breast cancerCurr Treat Options Oncol20034151812594941
   PubMedGoogle Scholar
• LiuGFranssenEFitchMIPatient preferences for oral versus intravenous palliative chemotherapyJ Clin Oncol19971511058996131
   PubMed Web of Science ®Google Scholar
• LuckmanSPHughesDECoxonFPNitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including RasJ Bone Miner Res19981358199556058
   PubMed Web of Science ®Google Scholar
• MajorPPLiptonABerensonJOral bisphosphonates: A review of clinical use in patients with bone metastasesCancer20008861410618600
   PubMed Web of Science ®Google Scholar
• MaldenNJPaiAYOral bisphosphonate associated osteonecrosis of the jaws: three case reportsBr Dent J200720393717660780
   PubMed Web of Science ®Google Scholar
• ManciniIDumonJCBodyJJEfficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot studyJ Clin Oncol20042235879215337809
   PubMed Web of Science ®Google Scholar
• MavrokokkiTChengASteinBNature and frequency of bisphosphonate-associated osteonecrosis of the jaws in AustraliaJ Oral Maxillofac Surg2007654152317307586
   PubMed Web of Science ®Google Scholar
• McLachlanSACameronDMurrayRSafety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experienceClin Drug Investig200626438
   PubMed Web of Science ®Google Scholar
• MichigamiTHiragaTWilliamsPJThe effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organsBreast Cancer Res Treat2002752495812353814
   PubMed Web of Science ®Google Scholar
• MonkkonenHAuriolaSLehenkariPA new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonatesBr J Pharmacol20061474374516402039
   PubMed Web of Science ®Google Scholar
• NavarroRPMorrowTBaranRPharmacoeconomic and clinical outcomes in oncology using oral chemotherapyManag Care Interface200215556212143298
   PubMedGoogle Scholar
• NobuyukiHHiragaTWilliamsPJThe bisphosphonate zoledronic acid inhibits metastases to bone and liver with suppression of osteopontin production in mouse mammary tumorJ Bone Miner Res200116Suppl 1S191
   Google Scholar
• NovartisPharmaAredia (pamidronate) Prescribing information
   Google Scholar
• NovartisPharmaZometa (zoledronic acid) Prescribing Information
   Google Scholar
• OliffAFarnesyltransferase inhibitors: targeting the molecular basis of cancerBiochim Biophys Acta19991423C193010382537
   PubMed Web of Science ®Google Scholar
• PaleyMLoveNCarlsonRPreferences for oral and parenteral antitumor therapy: a survey of 260 patients with metastatic breast cancerProc Am Soc Clin Oncol200523619
   PubMed Web of Science ®Google Scholar
• PatersonAHPowlesTJKanisJADouble-blind controlled trial of oral clodronate in patients with bone metastases from breast cancerJ Clin Oncol19931159658418243
   PubMed Web of Science ®Google Scholar
• PavlakisNStocklerMBisphosphonates for breast cancerCochrane Database Syst Rev20021CD00347411869664
   PubMedGoogle Scholar
• PazianasMBlumentalsWAMillerPDLack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate markerOsteoporos Int2007Nov 13 Epub ahead of print
   Web of Science ®Google Scholar
• PecherstorferMRivkinSBodyJJLong-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trialClin Drug Investig20062631522
   PubMed Web of Science ®Google Scholar
• PfeilschifterJMundyGRModulation of type beta transforming growth factor activity in bone cultures by osteotropic hormonesProc Natl Acad Sci USA198784202483494250
   PubMed Web of Science ®Google Scholar
• PowlesTPatersonSKanisJARandomized, placebo-controlled trial of clodronate in patients with primary operable breast cancerJ Clin Oncol20022032192412149294
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDKaminskiMZoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trialCancer J200173778711693896
   PubMed Web of Science ®Google Scholar
• RussellRGCroucherPIRogersMJBisphosphonates: pharmacology, mechanisms of action and clinical usesOsteoporos Int19999Suppl 2S668010525729
   PubMed Web of Science ®Google Scholar
• RussellRGRogersMJFrithJCThe pharmacology of bisphosphonates and new insights into their mechanisms of actionJ Bone Miner Res199914Suppl 2536510510215
   PubMed Web of Science ®Google Scholar
• SzetoCCChowKMNephrotoxicity related to new therapeutic compoundsRen Fail2005273293315957551
   PubMed Web of Science ®Google Scholar
• TripathyDLichinitzerMLazarevAOral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trialAnn Oncol2004157435015111341
   PubMed Web of Science ®Google Scholar
• ZhangFLCaseyPJProtein prenylation: molecular mechanisms and functional consequencesAnnu Rev Biochem199665241698811180
   PubMed Web of Science ®Google Scholar